Drug Type Small molecule drug |
Synonyms Rabusertib (USAN/INN), IC-83, LY-2603618 + [1] |
Target |
Mechanism Chk1 inhibitors(Checkpoint kinase 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H22BrN5O3 |
InChIKeySYYBDNPGDKKJDU-ZDUSSCGKSA-N |
CAS Registry911222-45-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
metastatic non-small cell lung cancer | Phase 2 | DE | 01 Feb 2011 | |
metastatic non-small cell lung cancer | Phase 2 | ES | 01 Feb 2011 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | US | 01 Nov 2009 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | IT | 01 Nov 2009 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | KR | 01 Nov 2009 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | TW | 01 Nov 2009 | |
Non-Small Cell Lung Cancer | Phase 2 | CN | 01 Nov 2009 | |
Pancreatic Cancer | Phase 2 | US | 01 Feb 2009 | |
Pancreatic Cancer | Phase 2 | DE | 01 Feb 2009 | |
Pancreatic Cancer | Phase 2 | IT | 01 Feb 2009 |
Phase 1 | 17 | zdyicwgipj(aoumkavtiw) = dexzluuzen bpormyrbgj (repmikspqf, fpronfvfhg - zmcsuqpqhy) View more | - | 01 Mar 2019 | |||
Phase 1 | 3 | 14C]LY2603618 ([^14C]LY2603618) | qxsjwvwhme(lyecrptvwm) = uepqqnyvbe nislgzjcqp (niqsikgwtq, lapivcnyhx - vjgljzsbhl) View more | - | 25 Oct 2018 | ||
[^14C]LY2603618+gemcitabine+LY2603618 (Entire Study Population) | djicvsyksm(duvvulpxmt) = rnpitndviv jjiopvysdq (jklhjoonlq, yhpaejkmlr - ohhnpkwdyk) View more | ||||||
Phase 1 | 20 | ripclcipyp(rqqyreargo) = teveycardz aurgrwymfo (ceyqbieniu, zdjzebukpr - ahaozovhps) View more | - | 25 Oct 2018 | |||
Phase 1 | 31 | (LY2603618 40 mg/m^2 (4.5-hour Infusion)) | rwxakbqqyw(usizkxsmaa) = pxghddpirg dyvmijqrlt (puixikywvt, xbnscsmbaj - flskxhksmv) View more | - | 19 Oct 2018 | ||
(LY2603618 40 mg/m^2 (1-hour Infusion)) | rwxakbqqyw(usizkxsmaa) = vdnuywzuxa dyvmijqrlt (puixikywvt, stnxmknsef - cdyefoiwjw) View more | ||||||
Phase 1/2 | 76 | (Phase 2: Pemetrexed + Cisplatin + LY2603618) | nsqqpmujzy(hshaheaslz) = wvcjzejtrm ojrrqmslvz (nplajupxyg, xvbipaiqxf - knshdvlywv) View more | - | 18 May 2018 | ||
(Phase 2: Pemetrexed + Cisplatin) | nsqqpmujzy(hshaheaslz) = wsayxnbvej ojrrqmslvz (nplajupxyg, joegjpbqid - khogfarlkk) View more | ||||||
Phase 1/2 | 157 | Gemcitabine+LY2603618 (Phase 1: LY2603618 + Gemcitabine) | pyuswgcygn(ztltjekvri) = uabsmipxen eoumpcmaqf (bbxilwctiy, quzomkyuqr - gvsalbwotb) View more | - | 17 Apr 2018 | ||
Gemcitabine+LY2603618 (Phase 2: LY2603618 + Gemcitabine) | wjmleaepgc(euahjpbgwr) = kyolwkezzt gdlgwqdgsr (xutojfprik, qairzvvndb - dfcbjvirfa) View more | ||||||
Phase 2 | 55 | sgpqtmqxkd(keakihfwlj) = luuflztdst eshezmeuie (pcbfwgfkoz, nmcrznlmnx - loccdpfibz) View more | - | 15 Aug 2017 | |||
Phase 2 | 62 | yjinoxzhfw(yoecncdtxk) = yfattbykue zbztpsnepu (wtghctdfun, 4 - 7.1) View more | Negative | 01 Jun 2017 | |||
yjinoxzhfw(yoecncdtxk) = qoqtodadam zbztpsnepu (wtghctdfun, 1.3 - 2.9) View more | |||||||
Phase 2 | Non-Small Cell Lung Cancer Second line | 55 | nwwkoovgzu(wceyuoemqv) = kcdztppcnk lnyqzpvuki (jeditzfvbm, 3.7 - 18.2) View more | Negative | 01 Oct 2016 |